The skin lab behind the celebrity headline

Michael Polansky's Outer Biosciences keeps human skin alive for a month and trains an AI model on what happens to it. For an industry that argues about evidence every day, that lands closer to home than any celebrity launch.

TechCrunch published a profile this week of Michael Polansky, who is Lady Gaga's partner, a former deputy to Sean Parker, and the executive director of the Parker Institute for Cancer Immunotherapy. The beauty press will read that opening line and reach for the celebrity file. The business he has spent four years building sells research to the companies that formulate products, which places it much closer to the professional channel's daily arguments about evidence than the famous name would suggest.

What the company actually does

Outer Biosciences was co-founded in 2022 by Polansky as chief executive, chief scientist Kyung-Jin Jang, chief technology officer Chris Hinojosa, and chief business officer Stanley King. It sources human skin that would otherwise be discarded after surgery (mostly plastic surgery) through biobanks and brokers working under institutional review board oversight and documented donor consent. Samples arrive de-identified, with names and contact details stripped by the supplying organisations before anything reaches the lab. A proprietary support system then feeds the tissue and removes metabolic waste, which keeps it viable for up to a month.

The industry norm sits at a matter of days. Days are long enough to test for acute toxicity and nowhere near long enough to watch collagen remodelling, pigmentation change, barrier repair, or the inflammatory settling that follows UV exposure. Anyone who has told a client to give a new routine eight to twelve weeks already understands the problem, because skin biology runs on a timeline most laboratory testing cannot reach. Polansky's team can induce UVB damage in living tissue and then observe the stress and recovery responses that unfold over the weeks afterwards, watching an injury happen and watching the biology that follows it.

An AI model predicts which untested chemicals are likely to act on a specific skin function. Those chemicals run through the living tissue. The results, whether the prediction held or failed, feed back into the model and sharpen the next round of predictions. That closed loop is what Outer Biosciences sells today, a faster route to finding an ingredient rather than any single ingredient itself. All of the company's AI work runs on-premise, because as Polansky told TechCrunch, the team does not want the data sitting in the cloud.

The pace has changed considerably. Early on the team worked by brute force, mining scientific literature and partnering with the National Cancer Institute on natural compounds drawn from extreme environments, which produced a couple of leads across roughly eighteen months. With the model layered in, a new candidate now emerges about every six weeks, with six leads currently active and several dozen further hits logged. The company has raised around $23 million to date and employs nineteen people, almost all of them just outside Cambridge, Massachusetts.

The universe of skin actives is far smaller than a shelf of hero serums suggests. The FDA maintains rules covering thirteen categories of over-the-counter skin drugs, and across all of those categories only about 120 to 130 active ingredients are approved. Add the cosmetic ingredients with real research behind them and Polansky puts the working total near 200.

Two hundred explains a great deal about the professional channel. It explains why competing flagship formulas read so similarly on the back of the box, why so much brand differentiation ends up living in delivery systems and protocol design, and why the evidence conversation in salons and clinics so often comes back to the same handful of molecules wearing different trade names. Discovery of that kind has been slow because there has never been an ethical way to run experiments on people, leaving researchers with animal models, simplified cell cultures, and lab-grown organoids as stand-ins for how a real human organ behaves.

Because these are cosmetic ingredients, there is no FDA approval to chase. The route runs through a standardised industry name first, then safety testing under guidelines set by the OECD, whose member countries accept each other's properly run studies. A commercial partner takes it from there. Outer Biosciences plans to license or sell finished ingredients to beauty and pharmaceutical companies who will formulate and brand them, and four of the six current leads look likely to reach that point. Revenue today comes from collaborative research partnerships, including a pharmaceutical partner investigating why certain cancer drugs cause severe skin rashes, and consumer beauty brands testing whether the company's data holds up against their own development and marketing needs.

None of that moves at launch speed. Naming, safety testing, formulation, and manufacturing scale-up each carry their own timeline, and product development is still being handled by the same scientists who make the discoveries, with a dedicated team on the roadmap rather than in place. Nobody is dispensing this in a treatment room next season.

What it means for brands selling into the channel

The evidence bar keeps rising. Salon owners and clinicians field the "does it actually work" question every day, and they are increasingly well read. A category where month-long human tissue data exists is a category where twelve-week claims built on short-window cell studies start to look thin by comparison.

Ingredient novelty is coming back into play. Brands whose positioning rests on a proprietary complex have spent years differentiating within a small pool of molecules. A discovery engine producing a candidate every six weeks changes what the pool might look like by the end of the decade.

Licensing deals are the story to track. The interesting news arrives as an ingredient supplier announcement, an INCI listing, a formulation patent, or an understated line in a brand's technical materials about a complex nobody has seen before.

Better questions are available to you now. How long did the study run, what tissue was used, how many donors were involved, and what was actually measured. Those four questions separate marketing language from research, and any brand serious about the professional channel should be able to answer them without hesitation.

Outer Biosciences is one company's account of its own work, given to a reporter over coffee. Rivals are chasing the same prize from different directions, among them Vivodyne, which has raised close to $80 million for lab-grown human organ tissue, along with a field of organ-on-a-chip and microphysiological systems companies. The direction of travel is worth noting regardless of who arrives first. For an industry that has spent a decade making claims about actives on the back of cell cultures and short testing windows, living human tissue observed for a month is a far better answer to the question salons, clinics, spas, and stockists have been asking all along.